Equities Analysts Offer Predictions for AMLX FY2029 Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – HC Wainwright reduced their FY2029 earnings estimates for shares of Amylyx Pharmaceuticals in a note issued to investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn $1.66 per share for the year, down from their prior forecast of $1.79. HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2030 earnings at $3.74 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03).

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Citigroup increased their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Guggenheim boosted their price target on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Finally, Mizuho upped their price objective on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.38.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $22.67 on Monday. The business’s 50 day simple moving average is $17.54 and its two-hundred day simple moving average is $15.81. The firm has a market cap of $2.53 billion, a P/E ratio of -15.85 and a beta of -0.21. Amylyx Pharmaceuticals has a 52-week low of $7.61 and a 52-week high of $24.60.

Insider Buying and Selling

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Amylyx Pharmaceuticals by 10.1% during the 4th quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company’s stock worth $70,123,000 after purchasing an additional 531,162 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Amylyx Pharmaceuticals by 15.5% in the first quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company’s stock valued at $3,490,000 after purchasing an additional 33,757 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Amylyx Pharmaceuticals by 17.1% during the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock valued at $12,544,000 after purchasing an additional 131,944 shares during the period. iA Global Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the first quarter valued at $4,237,000. Finally, Siren L.L.C. purchased a new stake in Amylyx Pharmaceuticals in the first quarter worth $17,097,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.